Señales en vivo de VIGL | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 may 2024 @ 16:00):

Stats
Volumen de hoy	74 867.00
Volumen promedio	86 385.00
Capitalización de mercado	108.62M
EPS	$0 ( 2024-03-26 )
Próxima fecha de ganancias	( $-0.600 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.360
ATR14	$0.0180 (0.63%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-18	Kaufmann Petra	Buy	330 000	Stock Option Grant (Right to Buy)
2024-03-18	Kaufmann Petra	Buy	0
2024-03-01	Booth Bruce	Buy	34 612	Stock Option Grant (Right to Buy)
2024-03-01	Bruhn Suzanne Louise	Buy	24 073	Stock Option Grant (Right to Buy)
2024-03-01	Blanchard Cheryl R	Buy	24 761	Stock Option Grant (Right to Buy)

INSIDER POWER
99.98
Last 93 transactions
Buy: 32 103 135 \| Sell: 31 582 660

Volumen Correlación

Largo: 0.02 (neutral)

Corto: -0.50 (neutral)

Signal:(36.238) Neutral

Vigil Neuroscience, Inc. Correlación

10 Correlaciones Más Positivas
RMRM	0.816

10 Correlaciones Más Negativas
NETE	-0.824
SHSP	-0.81
IMRA	-0.803
BOCH	-0.801

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Vigil Neuroscience, Inc. Correlación - Moneda/Commodity

-0.30
( neutral )

-0.27
( neutral )

0.00
( neutral )

-0.44
( neutral )

0.02
( neutral )

0.11
( neutral )

Vigil Neuroscience, Inc. Finanzas

Annual	2023
Ingresos:	$0
Beneficio Bruto:	$-399 000 (0.00 %)
EPS:	$-2.13

FY	2023
Ingresos:	$0
Beneficio Bruto:	$-399 000 (0.00 %)
EPS:	$-2.13

FY	2022
Ingresos:	$0
Beneficio Bruto:	$-1.01M (0.00 %)
EPS:	$-2.14

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-1.531

Financial Reports:

No articles found.

Vigil Neuroscience, Inc.

Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts.

Actualizaciones en tiempo real para Vigil Neuroscience, Inc. [VIGL]

Upcoming Earnings Alert